Results 91 to 100 of about 6,464 (211)

Integrated Genomic and Phenotypic Analyses Reveal Convergent Resistance Patterns in Clinical Candida tropicalis Isolates

open access: yesMycoses, Volume 69, Issue 5, May 2026.
ABSTRACT Background The incidence of Candida tropicalis isolation is increasing in hospital settings. High azole resistance and mortality rates make it a pathogen that requires further analysis. Methods Fourteen azole resistant Candida glabrata clinical isolates were collected from a Lebanese hospital and analysed through whole genome sequencing for ...
Christy Chedraoui   +9 more
wiley   +1 more source

Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit [PDF]

open access: yes, 2009
Recent studies suggest that differences in antifungal activity among echinocandins may exist. In this study, the activities of three echinocandins (anidulafungin, caspofungin, and micafungin) against Candida parapsilosis isolates from burn unit patients,
Ghannoum, M.A.   +7 more
core   +1 more source

Immunocompromised Status Definition in Observational Studies Using Electronic Health Records: A Scoping Review and a Proposal for a Phenotype Identification Algorithm

open access: yesPharmacoepidemiology and Drug Safety, Volume 35, Issue 4, April 2026.
ABSTRACT Immunocompromised individuals experience an impaired immune function due to conditions that might be either congenital or acquired over the course of their lives. Epidemiological studies often rely on clinical definitions which, in some cases, benefit from being translated into machine‐readable algorithms for application to electronic health ...
Judit Riera‐Arnau   +62 more
wiley   +1 more source

Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia [PDF]

open access: yes, 2014
BackgroundAlthough echinocandins have high in vitro antifungal efficacy according to prior reports, comparative studies on the clinical cure rates of anidulafungin, caspofungin, and micafungin in systemic candida infections have not yet been reported ...
See, Lai-Chu   +5 more
core   +1 more source

The Epidemiology and Infection Control of Candida Auris in Shanghai

open access: yesMycoses, Volume 69, Issue 4, April 2026.
ABSTRACT Background Candida auris is a globally emerging multidrug‐resistant fungus. Its dissemination is driven by patient movement and asymptomatic carriers. However, molecular epidemiological studies linking imported cases to local strains in large metropolitan areas remain limited.
Mingjing Wei   +8 more
wiley   +1 more source

Multicenter Analysis of Anidulafungin Use in Invasive Candida Infections [PDF]

open access: yes, 2019
Giriş: Tüm dünyada fungal infeksiyonlar önemli bir sorun olup değişen hasta profili ile birlikte sıklığı artmıştır. Özellikle kandida halen en sık karşılaşılan fungal etken olup son yıllarda albikans dışı kandidaların önemi artmıştır.
Kutsoylu, Oya Eren   +6 more
core   +1 more source

Effectiveness and safety of echinocandins combination therapy with the standard of care compared to the standard of care monotherapy for the treatment of invasive aspergillosis infection: a meta-analysis

open access: yesFrontiers in Pharmacology
BackgroundThis meta-analysis aims to evaluate the effectiveness and safety of combining echinocandins with standard of care (SOC) antifungal drugs for treating invasive aspergillosis infection (IAI).MethodWe searched PubMed, Embase, and Cochrane Library ...
Yazed Saleh Alsowaida   +6 more
doaj   +1 more source

[Anidulafungin].

open access: yesRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2008
Anidulafungin is a new echinocandin antifungal agent recently approved in Spain by the Spanish Drug Agency. As other echinocandins, it inhibits a selective target, 1,3- beta-D-glucan synthesis, a major structural component of the fungal cell wall which is not present in mammalian cells, this avoiding toxicity problems.
M, Gobernado, E, Cantón
openaire   +1 more source

Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials [PDF]

open access: yes, 2017
Contains fulltext : 177342.pdf (Publisher’s version ) (Open Access)Objectives: To evaluate the efficacy of anidulafungin for the treatment of candidaemia and invasive candidiasis in a large dataset, including patients with deep-seated ...
José-Artur Paiva   +25 more
core   +1 more source

Anidulafungin in the treatment of patients with invasive candidiasis [PDF]

open access: yes, 2008
Echinocandins have emerged as important agents for the treatment of invasive candidiasis. Forthcoming guidelines are expected to recommend an echinocandin agent as initial primary therapy in patients who are severely ill and/or have risk factors for ...
Cubillos, G Fernando, Kett, Daniel H
core   +1 more source

Home - About - Disclaimer - Privacy